KKR deepens India healthcare bet with $1.39 billion Medicover acquisition

Global investment firm KKR has acquired Medicover India's hospital network for $1.39 billion. This acquisition marks KKR's third hospital purchase in recent years. Medicover India operates 24 multi-specialty hospitals across South and West India. The European healthcare chain will now focus its operations solely within the continent. This transaction allows Medicover to strengthen its financial position and pursue European growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zUcEjF
via IFTTT

Read More

Centre to bar drugmakers from selling mislabelled, fraudulently approved products under new provisions

New rules will bar drugmakers from selling products if false information was provided. The Union Ministry of Health & Family Welfare has amended the Drugs Rules, 1945. This adds accountability for drug manufacturers and distributors operating in the country. The Licensing Authority can now debar entities from filing future applications. This amendment aims to deter misconduct and ensure reliable drug approval evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B15tvuK
via IFTTT

Read More

KKR buys Medicover’s India hospitals business

Global investment firm KKR has acquired Medicover India's hospital business. Sources said the the transaction values the hospital chain at around ₹10,000 crore and KKR may invest another ₹3,000-4,000 crore to fuel expansion. The acquisition strengthens KKR's healthcare portfolio, adding Medicover's 24-hospital network while reinforcing its long-term strategy to capitalise on India's rapidly growing healthcare and hospital sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7foyniQ
via IFTTT

Read More

KKR to acquire Medicover India in $1.5 billion deal

The transaction includes a sale of 100% stake by existing shareholders, as well as a commitment to deploy fresh capital to fund its growth and repay debt. In all, KKR will be spending Rs 13,000-14,000 crore, around quarter of which (Rs 3,000-4,000 crore) will go into the company as primary capital, said people aware of developments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7YfatJ9
via IFTTT

Read More

Delhi HC seeks response on Natco's patent challenge plea

The Delhi High Court is reviewing Natco Pharma's challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition's maintainability after legal arguments. The case has been scheduled for further hearing on September 16.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m8p3J7K
via IFTTT

Read More

Cipla, Rocket India announce Rs 300 crore expansion plans in Karnataka; Blackstone eyes data centres

Cipla and Rocket India will invest Rs 300 crore in Karnataka's manufacturing facilities. Blackstone is exploring investments in data centers and renewable energy infrastructure. Saint-Gobain plans to expand its manufacturing footprint within the state. Horizon is encouraged to consider industrial projects in tier two cities. These announcements occurred during Karnataka's investment roadshow in Mumbai.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W46dIZb
via IFTTT

Read More

IPA seeks to regularise 'legacy' drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vClqPwm
via IFTTT

Read More